cdr3.jpg (9069 bytes)

Subscription

Reprints


Journal Home
Contents
Editorial Board
Instructions for Contributors
Subscription Rates


© Neva Press, Inc. 2005


Cardiovascular Drug Reviews

Instructions for Contributors


SCOPE.
  Cardiovascular Drug Reviews provides a medium for publication of review monographs on new or potential cardiovascular drugs.  The reviews cover the pharmacology, pharmacokinetics, toxicology, and clinical experience with these drugs.  All review articles are peer reviewed by members of the Editorial Board. 

ADDRESS FOR CONTRIBUTORS.  Send manuscripts to Alexander Scriabine, M.D., Editor-in-Chief, Cardiovascular Drug Reviews Editorial Office, 435 Colonial Road, Guilford, CT 06437, USA (E-mail:  info@nevapress.com) (Fax:  203-458-8428). 

MANUSCRIPT FORM.  Manuscript should be submitted in Microsoft Word as an attachment to E-mail.

Language.  Cardiovascular Drug Reviews is published in American English (e.g. epinephrine, edema, ischemia, normalized, etc.).  Consult Webster's Dictionary for spelling.

Title Page.  The title page should include a concise title, authors' names and affiliations, and an address to which correspondence and reprint requests should be sent.

Key Words.  List key words for index purposes on a separate page.  Consult Medical Subject Headings, Vol. 40, 1999 published by the National Institutes of Health (ISSN:  0019-3879).

Running Titles:  The running titles should be provided by the author.  The first title should include the first and second authors.  If there are more than two authors, list first author, et al.  The second title should consist of one or two words, preferably drug name or code number.

Abstract.  A 200 to 300 word abstract should be included with the manuscript.  Starting with Volume 18 (Year 2000) Cardiovascular Drug Reviews is publishing abstracts of all review articles on the web free of charge ().

Figures and Tables.  All illustrations should be submitted as an attachment to e-mail or as one set of glossy prints.  These should be professionally labeled and explanatory legends provided on a separate page.  On the back of each figure affix a label giving the figure number, author's name, and indicating the top of the figure.  The preferred size for prints is 12.5 x 17.5 cm (5 x 7 inches). Tables should be typed double spaced, without ruled lines.  Color printing is available for an additional charge.

References.  References should be numbered in the text and listed alphabetically, following the sample formats listed below, and typed double spaced at the end of the manuscript.  Provide all authors names when fewer than seven; when seven or more list only the first three, et al.  Provide article titles and inclusive pages.  Index Medicus abbreviations should be used for journal titles.  Accuracy of reference data is the responsibility of the author.  Sample styles are as follows:

Journal article

1.   Hara H, Toriu N, Shimazawa M.  Clinical potential of lomerizine, a Ca2+ channel blocker as an anti-glaucoma drug:  effect on ocular circulation and retinal neuronal damage.  Cardiovasc Drug Revs 2004;22:199-214.

Book

2.   Hardman JG, Limbird LE, Gilman AG:  Goodman & Gilman’s the pharmacological basis of therapeutics, 10th edition.  New York:  McGraw-Hill, 2001:1-2148.

Chapter in Book

3.   Evers As, Crowder CM.  General anesthetics.  In:  Goodman & Gilman’s the pharmacological basis of therapeutics, 10th edition.  New York:  McGraw-Hill, 2001:337-365.

Style Manuals.  Cardiovascular Drug Reviews is using the following style manuals:

1.   Scientific Style and Format.  The CBE Manual for Authors, Editors, and Publishers.  Sixth Edition.  Published by Cambridge University Press for Council of Biology Editors, Inc., Chicago, IL, 1994.

2.   List of Journals Indexed in Index Medicus.  National Library of Medicine, 2004.

PROOFS AND REPRINTS.  Proofs must be returned within 3 days of receipt; late return may cause a delay in publication.  Please check text, tables, legends, and references very carefully.  To expedite publication page proofs rather than galleys will be sent to authors, and it may, therefore, be necessary to charge for alterations other than correction of printer's errors.  Return proofs by fax (203-458-8428) or return the pdf file with notes attached by e-mail (info@nevapress.com).

PAGE CHARGE.  Manuscripts of 15 or fewer printed pages are published with no page charge.  For longer manuscripts there is a charge of $100.00 per printed page over 15.

COPYRIGHTS.  The authors should avoid the use of previously published Figures and Tables.  If such use is unavoidable, the author(s) should obtain written permission to use such material from publishers of the journals where it may have been published and provide Neva Press, Inc. with copies of the permissions, which should include electronic and translation rights.  Copyrights on all published articles will be held by the publisher, Neva Press.  In view of present U.S. copyright law, effective January 1, 1978, it is necessary that each author of a submitted manuscript sign a statement expressly transferring copyright in the event the paper is published in the journal.  After a manuscript has been accepted for publication, the Editorial Office will send a copyright transfer form to the corresponding author.  It is the responsibility of authors to obtain permission to reproduce (in printed and electronic formats) for any figures and tables, which were published previously.  This permission should be obtained from the authors and publishers who own the material.  Return assignment of copyright and reprint order forms to Cardiovascular Drug Reviews, Neva Press, P.O. Box 347, Branford, CT 06405, USA.